Global Antibiotics Partnering Directory 2010-2020: Updated Deals Covering Antibiotics, Aminoglycosides, Cephalosporin, Clindamycin, Macrolides, Penicillin,…

first_img Previous articleRaven Adds Smooth-Edge Technology to Extruded GeomembranesNext article‘Not like every time:’ Beirut blast victims want the truth Digital AIM Web Support Global Antibiotics Partnering Directory 2010-2020: Updated Deals Covering Antibiotics, Aminoglycosides, Cephalosporin, Clindamycin, Macrolides, Penicillin, Quinolones, Sulfonamides, Tetracycline – ResearchAndMarkets.com WhatsApp Pinterest Twitter Pinterest Facebook Local NewsBusinesscenter_img Twitter WhatsApp TAGS  DUBLIN–(BUSINESS WIRE)–Feb 4, 2021– The “Global Antibiotics Partnering Terms and Agreements 2010 to 2020” report has been added to ResearchAndMarkets.com’s offering. The Global Antibiotics Partnering Terms and Agreements 2010 to 2020 report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors antibiotics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not. This report contains over 300 links to online copies of actual antibiotics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal. Report scope Global Antibiotics Partnering Terms and Agreements 2010 to 2020 includes:Trends in antibiotics dealmaking in the biopharma industry since 2010Analysis of antibiotics deal structureAccess to headline, upfront, milestone and royalty dataCase studies of real-life antibiotics dealsAccess to over 300 antibiotics deal records and contract documents where availableThe leading antibody deals by value since 2010Most active antibiotics dealmakers since 2010The leading antibiotics partnering resources In Global Antibiotics Partnering Terms and Agreements 2010 to 2020, the available contracts are listed by:Company A-ZHeadline valueStage of development at signingDeal component typeSpecific therapy and technology target This report provides details of the latest antibiotics agreements announced in the healthcare sectors, covering:AntibioticsAminoglycosidesCephalosporinClindamycinMacrolidesPenicillinQuinolonesSulfonamidesTetracycline Key Topics Covered: Executive Summary Chapter 1 – Introduction Chapter 2 – Trends in antibiotics dealmaking 2.1. Introduction 2.2. Antibiotics partnering over the years 2.3. Most active antibiotics dealmakers 2.4. Antibiotics partnering by deal type 2.5. Antibiotics partnering by therapy area 2.6. Antibiotics partnering by industry sector 2.7. Deal terms for antibiotics partnering 2.7.1 Antibiotics partnering headline values 2.7.2 Antibiotics deal upfront payments 2.7.3 Antibiotics deal milestone payments 2.7.4 Antibiotics royalty rates 2.8. The anatomy of an antibiotics deal 2.8. a. Case study 1: RRD International & Dipexium Pharmaceuticals 2.8.b. Case study 2: Hospira & Cempra Pharmaceutical 2.8.c. Case study 3: Astellas & Optimer Pharmaceuticals Chapter 3 – Leading antibiotics deals 3.1. Introduction 3.2. Top antibiotics deals by value Chapter 4 – Most active antibiotics dealmakers 4.1. Introduction 4.2. Most active antibiotics dealmakers 4.3. Most active antibiotics partnering company profiles Chapter 5 – Antibiotics contracts dealmaking directory 5.1. Introduction 5.2. Antibiotics contracts dealmaking directory Chapter 6 – Antibiotics dealmaking by technology typeAntibioticsAminoglycosidesCephalosporinClindamycinMacrolidesMetronidazolePenicillinQuinolonesTetracycline Chapter 7 – Partnering resource center 7.1. Online partnering 7.2. Partnering events 7.3. Further reading on dealmaking For more information about this report visit https://www.researchandmarkets.com/r/i1wtx9 View source version on businesswire.com:https://www.businesswire.com/news/home/20210204005800/en/ CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL SOURCE: Research and Markets Copyright Business Wire 2021. PUB: 02/04/2021 11:01 AM/DISC: 02/04/2021 11:01 AM http://www.businesswire.com/news/home/20210204005800/en Facebook By Digital AIM Web Support – February 4, 2021 last_img

Published by

Leave a Reply

Your email address will not be published. Required fields are marked *